Evidence map›Paper›PMID 42477158›Full record

ArticleBone marrow transplantation2026

Is the adult EBMT risk score valid and relevant for hematopoietic stem cell transplantation in children acute leukemia?

F Baleydier, J E Galimard, F Bernard, F Gonzales, A Dalissier, A Al-Seraihy, J-H Dalle, C R S Uppugunduri, L Zubarovskaya, M Zecca and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

F BaleydierPaediatric Onco-Haematology Unit, Geneva University Hospital, Geneva, Switzerland. frederic.baleydier@hug.ch.ORCID http://orcid.org/0000-0002-8059-3015
J E GalimardEBMT Paris Study Unit, Paris, France.ORCID http://orcid.org/0000-0001-9102-4427
F BernardPaediatric Onco-Haematology Unit, Geneva University Hospital, Geneva, Switzerland.
F GonzalesPaediatric Onco-Haematology Unit, Geneva University Hospital, Geneva, Switzerland.
A DalissierEBMT Paris Study Unit, Paris, France.
A Al-SeraihyKing Faisal Specialist Hospital & Research Centre, Jeddah, Saudi Arabia.ORCID http://orcid.org/0000-0002-6509-8526
J-H DalleDepartment of Paediatric Haematology and immunology, Robert Debré Hospital, GHU AP-HP Nord, Université Paris Cité, Paris, France.ORCID http://orcid.org/0000-0002-8406-0793
C R S UppugunduriCansearch Research platform for pediatric oncology and hematology, Faculty of Medicine, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland.ORCID http://orcid.org/0000-0002-8928-7049
L ZubarovskayaRM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia.
M ZeccaPediatric Hematology-Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.ORCID http://orcid.org/0000-0002-8818-1744
F LocatelliIRRCS Ospedale Pediatrico Bambino Gesù, Sapienza University of Rome, Rome, Italy.ORCID http://orcid.org/0000-0002-7976-3654
A KulaginRM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia.ORCID http://orcid.org/0000-0002-9589-4136
F FagioliOnco-Ematologia Pediatrica Centro Trapianti Cellule Staminali, Torino, Italy.ORCID http://orcid.org/0000-0002-9257-900X
S RobinsonDepartment of Paediatric Oncology/BMT, Bristol Royal Hospital for Children, Bristol, UK.
A BalduzziPediatric Hematopoietic Stem Cell Transplant Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.ORCID http://orcid.org/0000-0002-5879-0610
A BiffiDivision of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Padova, Padova, Italy.ORCID http://orcid.org/0000-0002-4610-0870
Y ChalandonHaematology division and Bone Marrow Transplantation Unit, Geneva University Hospital, Geneva, Switzerland.ORCID http://orcid.org/0000-0001-9341-8104
P BaderDivision for Stem Cell Transplantation and Immunology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.ORCID http://orcid.org/0000-0003-4554-0265
S CorbaciogluDepartment of Paediatric Haematology, Oncology and Stem Cell Transplantation, University Hospital of Regensburg, Regensburg, Germany.
Krzysztof KalwakClinical Department of Pediatric BMT, Hematology and Oncology, Wroclaw Medical University, Wroclaw, Poland.ORCID http://orcid.org/0000-0003-1174-5799
M AnsariPaediatric Onco-Haematology Unit, Geneva University Hospital, Geneva, Switzerland.
Paediatric Diseases Working Party (PDWP) of European Society for Blood and Marrow Transplantation (EBMT)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The EBMT risk score, incorporating five factors to estimate the risks associated with haematopoietic stem cell transplantation (HSCT) in adult patients, has not been validated in children. This study aims to assess this score in 9447 children undergoing allogeneic HSCT for acute lymphoblastic or myeloid leukemia (ALL/AML) between 2010 and 2021. Risk factors were coded according to the original EBMT score. In both ALL (n = 5774) and AML (n = 3673), only disease status and the time from diagnosis to HSCT significantly impacted all the outcomes in the multivariable analysis. The combination of female donors and male recipients did not affect overall survival (OS), relapse incidence (RI), non-relapse mortality (NRM), and leukemia-free survival (LFS). Additionally, the prognostic impact of donor type was not evident; when viewed as two modalities, the impact of MSD versus non-MSD on different outcomes in ALL was inconsistent with those observed in AML. Consequently, in both ALL and AML, scores ranging from 3 to 5 significantly affected all outcomes, whereas a score of 2 did not significantly impact NRM or RI in AML. Therefore, this analysis demonstrates that the adult EBMT risk score is not entirely reliable in children with acute leukemia, highlighting the need for a new pediatric-specific prognostic score.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentAdultChildChild, PreschoolDisease-Free SurvivalFemaleHumansInfantMalePrognosisRisk AssessmentRisk Factors

Identifiers

PMID42477158

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.